I. Barneto

2.2k total citations · 1 hit paper
39 papers, 1.2k citations indexed

About

I. Barneto is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, I. Barneto has authored 39 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in I. Barneto's work include Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (12 papers) and Cancer therapeutics and mechanisms (10 papers). I. Barneto is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (12 papers) and Cancer therapeutics and mechanisms (10 papers). I. Barneto collaborates with scholars based in Spain, Mexico and Japan. I. Barneto's co-authors include Á. Artal, P. Lianes, J.L. González-Larriba, Alfredo Carrato, María Josefa Díez Dapena, Benito Valdés Castrillón, Catalina Vadell, Joaquín Montalar, Bartomeu Massutí and Rafael Rosell and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

I. Barneto

37 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atlas polínico de Andalucía Occidental

1987 127 citations I. Barneto et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
I. Barneto Spain	13	759	622	331	118	118	39	1.2k
Milada Zemanová Czechia	18	590 0.8×	820 1.3×	323 1.0×	150 1.3×	213 1.8×	66	1.3k
James Kuo United States	14	366 0.5×	282 0.5×	378 1.1×	116 1.0×	125 1.1×	33	1.2k
Mikinori Miyazaki Japan	13	375 0.5×	202 0.3×	303 0.9×	73 0.6×	81 0.7×	32	889
S. Caruso Italy	19	253 0.3×	358 0.6×	108 0.3×	458 3.9×	108 0.9×	61	1.2k
V. Costantini Italy	18	268 0.4×	232 0.4×	244 0.7×	108 0.9×	248 2.1×	35	1.1k
Maria Monne Italy	17	541 0.7×	431 0.7×	628 1.9×	99 0.8×	248 2.1×	38	1.5k
Sofie Isebaert Belgium	23	213 0.3×	1.2k 1.9×	437 1.3×	107 0.9×	101 0.9×	63	1.8k
Izumi Nakamura Japan	19	212 0.3×	104 0.2×	333 1.0×	78 0.7×	91 0.8×	57	893
Akitoshi Kinoshita Japan	19	516 0.7×	198 0.3×	440 1.3×	96 0.8×	33 0.3×	93	1.2k
Barnabás Wichmann Hungary	24	462 0.6×	168 0.3×	803 2.4×	100 0.8×	574 4.9×	67	1.4k

Countries citing papers authored by I. Barneto

Since Specialization

Citations

This map shows the geographic impact of I. Barneto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Barneto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Barneto more than expected).

Fields of papers citing papers by I. Barneto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Barneto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Barneto. The network helps show where I. Barneto may publish in the future.

Co-authorship network of co-authors of I. Barneto

This figure shows the co-authorship network connecting the top 25 collaborators of I. Barneto. A scholar is included among the top collaborators of I. Barneto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Barneto. I. Barneto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

López-González, Javier, et al.. (2024). A new updated prognostic index for patients with brain metastases (BMs) treated with palliative whole brain radiotherapy (WBRT) in the era of precision oncology. METASNCore project. Journal of Neuro-Oncology. 167(3). 407–413. 3 indexed citations

Ciruelos, Eva, Dolores Isla, Rafael López‐López, et al.. (2019). Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer. European Journal of Cancer Care. 28(6). e13164–e13164. 19 indexed citations

Arriola, Edurne, Ramón García Gómez, Pilar Díz, et al.. (2018). Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. BMC Cancer. 18(1). 106–106. 14 indexed citations

Sánchez-Gastaldo, Amparo, I. Barneto, Reyes Bernabé, et al.. (2018). P2.04-24 Nivolumab in the "Real World": Are the Results of Clinical Trials Reproducible?. Journal of Thoracic Oncology. 13(10). S739–S740. 1 indexed citations

Provencio, Mariano, Ernest Nadal, Amelia Insa, et al.. (2018). OA01.05 Phase II Study of Neo-Adjuvant Chemo/Immunotherapy for Resectable Stages IIIA Non-Small Cell Lung Cancer- Nadim Study-SLCG. Journal of Thoracic Oncology. 13(10). S320–S320. 5 indexed citations

Pérez‐Segura, Pedro, Susana Monereo, R. de las Peñas, et al.. (2017). Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology. Clinical & Translational Oncology. 19(6). 682–694.

Massutí, Bartomeu, Manuel Cobo, Iván Ballesteros, et al.. (2017). PL 02.04 SCAT Ph III Trial: Adjuvant CT Based on BRCA1 Levels in NSCLC N+ Resected Patients. Final Survival Results a Spanish Lung Cancer Group Trial. Journal of Thoracic Oncology. 12(11). S1605–S1605. 5 indexed citations

Goday, Albert, I. Barneto, José Manuel García‐Almeida, et al.. (2015). Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology. Clinical & Translational Oncology. 17(10). 763–771. 22 indexed citations

Muñoz-Langa, José, Javier de Castro, Emilio Esteban, et al.. (2015). Chemotherapy-associated anemia in patients with lung cancer: an epidemiological, retrospective and multicenter study. Future Oncology. 11(11). 1665–1674. 6 indexed citations

10.

Massutí, Bartomeu, Ulpiano Jiménez, J.M. Rodríguez Paniagua, et al.. (2011). SCAT trial: Phase III Spanish customized adjuvant treatment according BRCA1 mRNA levels in stage II-IIIA non-small cell lung cancer.. Journal of Clinical Oncology. 29(15_suppl). TPS208–TPS208. 1 indexed citations

11.

Safont, María José, Rafael Sirera, José Gómez‐Codina, et al.. (2008). Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer. Lung Cancer. 63(1). 83–87. 9 indexed citations

12.

Isla, Dolores, Carme Sarries, Rafael Rosell, et al.. (2004). Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer. Annals of Oncology. 15(8). 1194–1203. 255 indexed citations

13.

Felip, Enriqueta, Rafael Rosell, Vicente Alberola, et al.. (2000). Preoperative High-Dose Cisplatin Versus Moderate- Dose Cisplatin Combined with Ifosfamide and Mitomycin in Stage IIIA (N2) Non–Small-Cell Lung Cancer: Results of a Randomized Multicenter Trial. Clinical Lung Cancer. 1(4). 287–293. 8 indexed citations

14.

Font, Albert, A. Trés, Carlos García Girón, et al.. (1999). Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma. Cancer. 85(4). 855–863. 24 indexed citations

15.

Sánchez‐Rovira, Pedro, et al.. (1998). Serum levels of intercellular adhesion molecule 1 (ICAM-1) in patients with colorectal cancer: inhibitory effect on cytotoxicity. European Journal of Cancer. 34(3). 394–398. 37 indexed citations

16.

Antón, A., J.L. González-Larriba, Catalina Vadell, et al.. (1998). Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC). Lung Cancer. 22(2). 139–148. 35 indexed citations

17.

Aranda, Enrique, Eduardo Díaz‐Rubio, Andrés Cervantes, et al.. (1998). Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. Annals of Oncology. 9(7). 727–731. 78 indexed citations

18.

Barneto, I., et al.. (1997). 204 Phase II activity of cisplatin (CDDP) plus ifosfamide (IFO) and gemcitabine (GEM) in non small cell lung cancer (NSCLC): Preliminary results. Lung Cancer. 18. 53–53. 3 indexed citations

19.

Aranda, Enrique, et al.. (1995). Prevention of Highly Emetogenic Chemotherapy-Induced Vomiting: A Double Blind, Randomized Crossover Study to Compare Pancopride (LAS 30451) and Pancopride plus Dexamethasone. Tumori Journal. 81(6). 432–434. 1 indexed citations

20.

Díaz‐Rubio, Eduardo, et al.. (1990). Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer. European Journal of Cancer and Clinical Oncology. 26(6). 727–729. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact